Skip to main content
. 2021 Apr 14;16(4):e0249565. doi: 10.1371/journal.pone.0249565

Fig 1. Flowchart of the selected study population with MDR/RR-TB in Colombia, 2013–2015.

Fig 1

(TB: tuberculosis; XDR: extensive drug resistance; MDR: multidrug resistance; RMP: rifampicin; INH: isoniazid; INH without RMP: mono- or polyresistance to isoniazid that does not include rifampicin; other resistance: resistance to any antituberculosis drug other than RMP and INH).